InBioGen Co Ltd (101140) — Cash Flow-to-Debt Ratio
InBioGen Co Ltd (101140) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of ₩-1.67 Billion could theoretically repay -1% of its total liabilities (₩2.44 Billion) in one year. Explore 101140 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
InBioGen Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for InBioGen Co Ltd across 12 annual periods. Also explore InBioGen Co Ltd (101140) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for InBioGen Co Ltd (2013–2024)
Year-by-year debt coverage analysis for InBioGen Co Ltd. For market capitalisation and broader financial context, see InBioGen Co Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-33.13 Million | ₩2.89 Billion | ▲ +97.1% |
| 2023 | -0.40x | ₩-1.05 Billion | ₩2.62 Billion | ▼ -30.3% |
| 2022 | -0.31x | ₩-11.51 Billion | ₩37.40 Billion | ▼ -319.7% |
| 2021 | -0.07x | ₩-7.07 Billion | ₩96.45 Billion | ▲ +82.7% |
| 2020 | -0.42x | ₩-8.03 Billion | ₩18.97 Billion | ▼ -175.6% |
| 2019 | -0.15x | ₩-3.83 Billion | ₩24.92 Billion | ▲ +91.2% |
| 2018 | -1.75x | ₩-1.70 Billion | ₩968.80 Million | ▼ -749.2% |
| 2017 | -0.21x | ₩-426.44 Million | ₩2.07 Billion | ▼ -496.8% |
| 2016 | 0.05x | ₩344.75 Million | ₩6.62 Billion | ▲ +103.2% |
| 2015 | -1.62x | ₩-10.96 Billion | ₩6.76 Billion | ▼ -595.5% |
| 2014 | -0.23x | ₩-695.95 Million | ₩2.99 Billion | ▼ -30.4% |
| 2013 | -0.18x | ₩-1.13 Billion | ₩6.33 Billion | — |